Archer Materials (ASX:AXE) is advancing into the feasibility stage the development of the graphene field effect transistor (gFET) sensors for its Biochip, according to a Thursday filing with the Australian bourse.
The company built a dataset of the sensor's performance to advance the feasibility development of the Biochip for its application in blood potassium testing for chronic kidney disease, the filing said.
Archer Materials developed an initial electrical conditioning procedure, which sets individual gFETs to a state of high repeatability. This conditioning resulted in a tenfold improvement in voltage sweeping repeatability, directly enhancing the accuracy of potassium measurements, per the filing.
The company has also completed a round of benchmarking experiments with collaborators at RMIT University to further validate the performance entitlements of gFET sensors.
Archer Materials shares rose almost 2% in recent Friday trade.
Price (AUD): $0.31, Change: $+0.01, Percent Change: +1.64%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。